1. Home
  2. EDSA

as 07-26-2024 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.

Founded: 2015 Country:
Canada
Canada
Employees: N/A City: MARKHAM
Market Cap: 13.7M IPO Year: N/A
Target Price: $39.00 AVG Volume (30 days): 7.3K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.37 EPS Growth: N/A
52 Week Low/High: $2.46 - $8.33 Next Earning Date: 08-07-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

EDSA Daily Stock ML Predictions

Stock Insider Trading Activity of Edesa Biotech Inc. (EDSA)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Nijhawan Pardeep EDSA Chief Executive Officer Mar 25 '24 Buy $4.00 5,000 $20,000.00 341,702 SEC Form 4

Share on Social Networks: